Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D B Dixon

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Journal of Cardiovascular Pharmacology|January 1, 1995
Dissociation characteristics of endothelin ETA receptor agonists and antagonistsJ R Wu-Wong, W J Chiou, D B Dixon, et al.
The Journal of Investigative Dermatology|August 1, 1995
Amiloride blocks a keratinocyte nonspecific cation channel and inhibits Ca(++)-induced keratinocyte differentiationT Mauro, D B Dixon, K Hanley, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1997
Endothelin receptor antagonists: effect of serum albumin on potency and comparison of pharmacological characteristicsJ R Wu-Wong, D B Dixon, W J Chiou, et al.
Journal of Medicinal Chemistry|November 5, 1997
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ETA/ETB mixed antagonistsH S Jae, M Winn, D B Dixon, et al.
Journal of Medicinal Chemistry|February 16, 1996
Azole endothelin antagonists. 1. A receptor model explains an unusual structure-activity profileT W von Geldern, C Hutchins, J A Kester, et al.
Journal of Medicinal Chemistry|February 16, 1996
Azole endothelin antagonists. 2. Structure-activity studiesT W von Geldern, J A Kester, R Bal, et al.
Urology|May 1, 1999
New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockadeJ B Nelson, S H Nguyen, J R Wu-Wong, et al.
Journal of Cardiovascular Pharmacology|November 15, 2000
Effects of endothelin receptor antagonists on the plasma immunoreactive endothelin-1 levelT J Opgenorth, J L Wessale, D B Dixon, et al.
Journal of Medicinal Chemistry|September 10, 1999
Design, synthesis, and activity of a series of pyrrolidine-3-carboxylic acid-based, highly specific, orally active ET(B) antagonists containing a diphenylmethylamine acetamide side chainG Liu, N S Kozmina, M Winn, et al.
Life Sciences|November 24, 1998
The effects of diminishing albumin binding to some Endothelin receptor antagonistsB G Szczepankiewicz, R B Bal, T W von Geldern, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Journal of Cardiovascular Pharmacology|January 1, 1995
Dissociation characteristics of endothelin ETA receptor agonists and antagonistsJ R Wu-Wong, W J Chiou, D B Dixon, et al.
The Journal of Investigative Dermatology|August 1, 1995
Amiloride blocks a keratinocyte nonspecific cation channel and inhibits Ca(++)-induced keratinocyte differentiationT Mauro, D B Dixon, K Hanley, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1997
Endothelin receptor antagonists: effect of serum albumin on potency and comparison of pharmacological characteristicsJ R Wu-Wong, D B Dixon, W J Chiou, et al.
Journal of Medicinal Chemistry|November 5, 1997
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ETA/ETB mixed antagonistsH S Jae, M Winn, D B Dixon, et al.
Journal of Medicinal Chemistry|February 16, 1996
Azole endothelin antagonists. 1. A receptor model explains an unusual structure-activity profileT W von Geldern, C Hutchins, J A Kester, et al.
Journal of Medicinal Chemistry|February 16, 1996
Azole endothelin antagonists. 2. Structure-activity studiesT W von Geldern, J A Kester, R Bal, et al.
Urology|May 1, 1999
New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockadeJ B Nelson, S H Nguyen, J R Wu-Wong, et al.
Journal of Cardiovascular Pharmacology|November 15, 2000
Effects of endothelin receptor antagonists on the plasma immunoreactive endothelin-1 levelT J Opgenorth, J L Wessale, D B Dixon, et al.
Journal of Medicinal Chemistry|September 10, 1999
Design, synthesis, and activity of a series of pyrrolidine-3-carboxylic acid-based, highly specific, orally active ET(B) antagonists containing a diphenylmethylamine acetamide side chainG Liu, N S Kozmina, M Winn, et al.
Life Sciences|November 24, 1998
The effects of diminishing albumin binding to some Endothelin receptor antagonistsB G Szczepankiewicz, R B Bal, T W von Geldern, et al.
Pageof 3